PURPOSE: This study was conducted to characterize the effect of food on the relative bioavailability of lapatinib. PATIENTS AND METHODS: A single 1,500-mg, oral dose of lapatinib was administered to 27 patients with advanced solid tumors on each of three occasions that were 1 week apart, in random order: after an overnight fast, with a low-fat breakfast, and with a high-fat breakfast. RESULTS: The low-fat breakfast produced mean increases in lapatinib area under the concentration-time curve (AUC) of 167% (2.67-fold) and maximum concentration (C(max)) of 142% (2.42-fold). The high-fat breakfast produced mean increases in lapatinib AUC of 325% (4.25-fold) and C(max) of 203% (3.03-fold) compared with the fasted state. Increased bioavailability in the fed state did not significantly decrease relative variability. Therefore, absolute variability in systemic exposure was increased. CONCLUSION: These large increases in lapatinib bioavailability and absolute variability support the recommendation for dosing in the fasted state to achieve consistent therapeutic exposure. Prescribers and patients should consider the potential consequences of toxicity or diminished efficacy that might result from dosing without regard to variations in diet.
RCT Entities:
PURPOSE: This study was conducted to characterize the effect of food on the relative bioavailability of lapatinib. PATIENTS AND METHODS: A single 1,500-mg, oral dose of lapatinib was administered to 27 patients with advanced solid tumors on each of three occasions that were 1 week apart, in random order: after an overnight fast, with a low-fat breakfast, and with a high-fat breakfast. RESULTS: The low-fat breakfast produced mean increases in lapatinib area under the concentration-time curve (AUC) of 167% (2.67-fold) and maximum concentration (C(max)) of 142% (2.42-fold). The high-fat breakfast produced mean increases in lapatinib AUC of 325% (4.25-fold) and C(max) of 203% (3.03-fold) compared with the fasted state. Increased bioavailability in the fed state did not significantly decrease relative variability. Therefore, absolute variability in systemic exposure was increased. CONCLUSION: These large increases in lapatinib bioavailability and absolute variability support the recommendation for dosing in the fasted state to achieve consistent therapeutic exposure. Prescribers and patients should consider the potential consequences of toxicity or diminished efficacy that might result from dosing without regard to variations in diet.
Authors: John R Johnson; Martin Cohen; Rajeshwari Sridhara; Yeh-Fong Chen; Gene M Williams; John Duan; Jogarao Gobburu; Brian Booth; Kimberly Benson; John Leighton; Li Shan Hsieh; Nallalerumal Chidambaram; Paul Zimmerman; Richard Pazdur Journal: Clin Cancer Res Date: 2005-09-15 Impact factor: 12.531
Authors: Neil L Spector; Yosef Yarden; Bradley Smith; Ljuba Lyass; Patricia Trusk; Karen Pry; Jason E Hill; Wenle Xia; Rony Seger; Sarah S Bacus Journal: Proc Natl Acad Sci U S A Date: 2007-06-07 Impact factor: 11.205
Authors: Huixin Yu; Neeltje Steeghs; Cynthia M Nijenhuis; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema Journal: Clin Pharmacokinet Date: 2014-04 Impact factor: 6.447
Authors: Shirish M Gadgeel; Danika L Lew; Timothy W Synold; Patricia LoRusso; Vincent Chung; Scott D Christensen; David C Smith; Laura Kingsbury; Antje Hoering; Razelle Kurzrock Journal: Cancer Chemother Pharmacol Date: 2013-09-22 Impact factor: 3.333
Authors: Jianyuan Deng; Xiao Zhu; Zongmeng Chen; Chun Ho Fan; Him Shek Kwan; Chi Ho Wong; Ka Yi Shek; Zhong Zuo; Tai Ning Lam Journal: Drugs Date: 2017-11 Impact factor: 9.546
Authors: A Jo Chien; Pamela N Munster; Michelle E Melisko; Hope S Rugo; John W Park; Andrei Goga; Glenna Auerback; Elham Khanafshar; Karen Ordovas; Kevin M Koch; Mark M Moasser Journal: J Clin Oncol Date: 2014-04-07 Impact factor: 44.544